- $4.20bn
- $3.48bn
- 37
- 26
- 92
- 50
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 5.99 | ||
| Price to Tang. Book | 5.99 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -21.34% | ||
| Return on Equity | -21.7% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | 0.69 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Nuvalent, Inc. is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer. It develops small molecules that have the potential to overcome resistance, minimize adverse events, address brain metastases and drive more durable responses. It is advancing a robust pipeline with investigational candidates for ROS1-positive, ALK-positive, and HER2-positive non-small cell lung cancer, and multiple discovery-stage research programs. Its product candidate, NVL-520, is being developed for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC). NVL-520 is a novel ROS1-selective inhibitor. Its product candidate, NVL-655, is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC. LC. NVL-655 is a brain-penetrant ALK-selective inhibitor. Its product candidate, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor.
Directors
- James Porter PRE (46)
- Alexandra Balcom CFO (37)
- Darlene Noci SVP (44)
- Ruth Adams VOP
- Benjamin Lane VPR
- Joshua Horan SDR
- Deborah Miller OTH (46)
- Christopher Turner OTH (53)
- Matthew Shair DRC (53)
- Emily Conley IND
- D. Gary Gilliland NID (67)
- Andrew Hack NID (48)
- Robert Jackson NID (59)
- Joseph Pearlberg NID (57)
- Sapna Srivastava NID (50)
- Cameron Wheeler NID (43)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- January 25th, 2017
- Public Since
- July 29th, 2021
- No. of Shareholders
- 11
- No. of Employees
- 92
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 64,067,638
- Address
- One Broadway, 14th Floor, CAMBRIDGE, 02142
- Web
- https://www.nuvalent.com/
- Phone
- +1 8573577000
- Auditors
- KPMG LLP
Upcoming Events for NUVL
Similar to NUVL
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
As of Today at 19:15 UTC, shares in Nuvalent are trading at $65.51. This share price information is delayed by 15 minutes.
Shares in Nuvalent last closed at $65.51 and the price had moved by +128.74% over the past 365 days. In terms of relative price strength the Nuvalent share price has outperformed the S&P500 Index by +84.73% over the past year.
The overall consensus recommendation for Nuvalent is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Nuvalent does not currently pay a dividend.
Nuvalent does not currently pay a dividend.
Nuvalent does not currently pay a dividend.
To buy shares in Nuvalent you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $65.51, shares in Nuvalent had a market capitalisation of $4.20bn.
Here are the trading details for Nuvalent:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: NUVL
Based on an overall assessment of its quality, value and momentum Nuvalent is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Nuvalent is $102.14. That is 55.92% above the last closing price of $65.51.
Analysts covering Nuvalent currently have a consensus Earnings Per Share (EPS) forecast of -$2.95 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Nuvalent. Over the past six months, its share price has underperformed the S&P500 Index by -3.56%.
As of the last closing price of $65.51, shares in Nuvalent were trading +5.81% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Nuvalent PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $65.51.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Nuvalent's management team is headed by:
- James Porter - PRE
- Alexandra Balcom - CFO
- Darlene Noci - SVP
- Ruth Adams - VOP
- Benjamin Lane - VPR
- Joshua Horan - SDR
- Deborah Miller - OTH
- Christopher Turner - OTH
- Matthew Shair - DRC
- Emily Conley - IND
- D. Gary Gilliland - NID
- Andrew Hack - NID
- Robert Jackson - NID
- Joseph Pearlberg - NID
- Sapna Srivastava - NID
- Cameron Wheeler - NID